Cardio-Oncology
Research activity centers on the detection of cardiotoxicity in oncology patients receiving anthracycline-based antineoplastic therapy, with attention to early myocardial damage associated with cancer treatment.
- Anthracycline-related cardiotoxicity
- Oncology patient cardiac monitoring
- Myocardial injury detection
The clinical focus includes identifying cardiac complications linked to routine cancer therapy and supporting safer management of patients exposed to anthracyclines.
Cardiac Imaging
The sponsor’s work involves cardiac magnetic resonance imaging with contrast agents, reflecting interest in advanced imaging methods for assessing treatment-related heart effects.
- Cardiac magnetic resonance
- Contrast-enhanced imaging
- Serial cardiac assessment
This area supports detailed evaluation of cardiac structure and function during cancer therapy, with emphasis on early recognition of imaging changes consistent with cardiac injury.
Biomarker Analysis
Research includes biomarker analysis alongside imaging to explore biochemical signals associated with emerging cardiac toxicity in patients undergoing cancer treatment.
- Cardiac biomarkers
- Toxicity surveillance
- Early injury indicators
The combination of laboratory markers and imaging is directed toward improving recognition of subtle treatment-related changes in the heart.
Clinical Pharmacology
As an institute of clinical pharmacology, the sponsor is engaged in research at the interface of drug treatment and organ safety, particularly where anticancer therapy affects cardiovascular health.
- Drug-related organ toxicity
- Cancer therapy safety
- Therapy-related cardiac effects
The research setting reflects a focus on the clinical consequences of pharmacologic cancer treatment and the monitoring of adverse effects in routine oncology care.
